Prescripción de estatinas según el estimador ASCVD en el Hospital Pablo Arturo Suárez, marzo 2021 a febrero 2022
Barra lateral del artículo
Detalles del artículo
Esta obra está bajo una licencia internacional Creative Commons Atribución-NoComercial-SinDerivadas 4.0.
La publicación es gratuita y sus contenidos se distribuyen con la licencia Creative Commons Atribución-NoComercial-SinDerivadas 4.0 Internacional (CC BY-NC-ND 4.0) . Los derechos de las obras publicadas en esta revista son propiedad del autor y este es libre de distribuir y difundir las mismas fuentes siempre y cuando cite correctamente la fuente de publicación, estos actos no sean con fines comerciales y no se generen obras derivadas.
Contenido principal del artículo
Resumen
A nivel mundial, la principal causa de muerte es la enfermedad cardiovascular. El estudio detalla la prescripción de estatinas en el Hospital Pablo Arturo Suárez de Ecuador entre marzo de 2021 y febrero de 2022, siguiendo la escala de riesgo ASCVD del Colegio Americano de Cardiología y la Asociación Americana del Corazón. Son 563 personas en este estudio transversal y retrospectivo: 70% mujeres, 30% hombres, 93.30% mestizos, 48.10% diabéticos, 62.30% hipertensos y 18.70% fumadores. El 26.10% de los pacientes recibía estatinas, siendo la simvastatina la más frecuente (96.60%). El riesgo cardiovascular medio en la población general fue de 15.52 ± 14.51%, el 44.99% de los sujetos tenía un riesgo inferior al 7.50%, y el 29% tenía un riesgo superior al 20%, con una diferencia estadísticamente significativa (p<0.001) según el sexo. El estudio determinó que el 58.60% de la población recibía una estatina o una dosis inadecuada.
Citas
Acevedo, M. et al. (2017) “Evaluation the American College of Cardiology and American Heart Association Predictive score for cardiovascular diseases,” Revista medica de Chile, 145(3), pp. 292–298. doi: 10.4067/S0034-98872017000300002.
Azevedo, T. dos A., Moreira, M. L. V. and Nucera, A. P. C. dos S. (2018) “Cardiovascular risk estimation by the ASCVD risk estimator application in a university hospital,” International Journal of Cardiovascular Sciences. doi: 10.5935/2359-4802.20180052.
Barceló, A. (2006) “Cardiovascular diseases in Latin America and the Caribbean,” Lancet, 368(9536), pp. 625–626. doi: 10.1016/S0140-6736(06)69223-4.
Bhatnagar, P. et al. (2016) “Trends in the epidemiology of cardiovascular disease in the UK,” Heart (British Cardiac Society), 102(24), pp. 1945–1952. doi: 10.1136/heartjnl-2016-309573.
Blood Pressure Lowering Treatment Trialists’ Collaboration (2014) “Blood pressure-lowering treatment based on cardiovascular risk: a meta-analysis of individual patient data,” Lancet, 384(9943), pp. 591–598. doi: 10.1016/S0140-6736(14)61212-5.
Capodanno, D. and Angiolillo, D. J. (2016) “Aspirin for primary cardiovascular risk prevention and beyond in diabetes mellitus,” Circulation, 134(20), pp. 1579–1594. doi: 10.1161/CIRCULATIONAHA.116.023164.
Cho, M. H. et al. (2018) “Effects of smoking habit change on all-cause mortality and cardiovascular diseases among patients with newly diagnosed diabetes in Korea,” Scientific reports, 8(1). doi: 10.1038/s41598-018-23729-0.
Gasevic, D., Ross, E. S. and Lear, S. A. (2015) “Ethnic differences in cardiovascular disease risk factors: A systematic review of North American evidence,” The Canadian journal of cardiology, 31(9), pp. 1169–1179. doi: 10.1016/j.cjca.2015.06.017.
Ghorpade, A. G. et al. (2015) “Estimation of the cardiovascular risk using World Health Organization/International Society of Hypertension (WHO/ISH) risk prediction charts in a rural population of South India,” International journal of health policy and management, 4(8), pp. 531–536. doi: 10.15171/ijhpm.2015.88.
Grundy, S. M. et al. (2019) “2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA guideline on the management of blood cholesterol: A report of the American college of cardiology/American heart association task force on clinical practice guidelines,” Journal of the American College of Cardiology, 73(24), pp. e285–e350. doi: 10.1016/j.jacc.2018.11.003.
Herttua, K. et al. (2016) “Poor adherence to statin and antihypertensive therapies as risk factors for fatal stroke,” Journal of the American College of Cardiology, 67(13), pp. 1507–1515. doi: 10.1016/j.jacc.2016.01.044.
National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) (2002) “Third report of the national cholesterol education program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (adult treatment panel III) final report,” Circulation, 106(25), pp. 3143–3421. doi: 10.1161/circ.106.25.3143.
Radovanovic, C. A. T. et al. (2014) “Arterial hypertension and other risk factors associated with cardiovascular diseases among adults,” Revista latino-americana de enfermagem, 22(4), pp. 547–553. doi: 10.1590/0104-1169.3345.2450.
Ramos, R. et al. (2018) “Statins for primary prevention of cardiovascular events and mortality in old and very old adults with and without type 2 diabetes: retrospective cohort study,” BMJ (Clinical research ed.), 362, p. k3359. doi: 10.1136/bmj.k3359.
Rawshani, Aidin et al. (2018) “Risk factors, mortality, and cardiovascular outcomes in patients with type 2 diabetes,” The New England journal of medicine, 379(7), pp. 633–644. doi: 10.1056/NEJMoa1800256.
Stone, N. J. et al. (2014) “2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines,” Journal of the American College of Cardiology, 63(25 Pt B), pp. 2889–2934. doi: 10.1016/j.jacc.2013.11.002.
Wong, N. D. et al. (2014) “Preventable coronary heart disease events from control of cardiovascular risk factors in US adults with diabetes (projections from utilizing the UKPDS risk engine),” The American journal of cardiology, 113(8), pp. 1356–1361. doi: 10.1016/j.amjcard.2013.12.042.
World Health Organization (WHO) (2017) On Medicine. Available at: https://blogs.biomedcentral.com/on-medicine/2017/09/28/world-heart-day-2017-at-the-heart-of-health/ (Accessed: May 22, 2022).